Clinical Trial Update: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Ifinatamab Deruxtecan (I-DXd) for patients with pretreatment extensive-stage small cell lung cancer (ES-SCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Ifinatamab Deruxtecan (Ifinatamab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING